MediciNova Announces Plans for a Phase 2 Trial of MN-001 (tipelukast) in NAFLD with Type 2 Diabetes Mellitus and Hypertriglyceridemia

MediciNova, Inc. announced that the FDA has completed its review of a Phase II clinical trial protocol to evaluate MN-001 (tipelukast) for the treatment of patients with non-alcoholic fatty liver disease, type 2 diabetes mellitus, and hypertriglyceridemia.